Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
about
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer TherapyUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Cardiac complications of chemotherapy: role of imaging.Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.Doxorubicin-induced cardiac mitochondrionopathy.Doxorubicin-induced alterations in cultured myocardial cells stimulate cytolytic T lymphocyte responsesCytolytic T lymphocytes and antibodies to myocytes in adriamycin-treated BALB/c mice. Evidence for immunity to drug-induced antigens.Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study.Alternative Biomarkers for Combined Biology.Characterization of the Changes in Cardiac Structure and Function in Mice Treated With Anthracyclines Using Serial Cardiac Magnetic Resonance Imaging.Doxorubicin (adriamycin) cardiomyopathy.p21(WAF1/Cip1/Sdi1) knockout mice respond to doxorubicin with reduced cardiotoxicityPrimary liposarcoma of the heart.
P2860
Q26743433-24E57971-99E6-4760-9BEA-4120DCA31A41Q27027354-EBD32BE6-DF03-444A-92C6-29936FB22206Q30401812-E064F2FA-CA43-4A34-839D-0342F1000054Q30415201-0D430AF5-A9F5-47C4-9093-C7D16499B1BDQ30446509-C9A8E96F-CEAA-41C8-A7BF-DCACFD36D640Q33565936-99C86591-4BE2-4B17-A84E-2D73DF771547Q35217039-E2C80960-D739-40CC-84D2-4A3A882CF0D9Q35811834-3D9A3472-F0F8-41C5-870F-B420DD76A599Q35830962-728C4940-87AC-40E9-B708-8B8E86CECC4CQ36613973-2E253A7F-C5CE-4CF9-AEC5-73C61B1BB2BDQ38747992-B3D620F0-7B2D-4F32-8EB4-F23D0E2C2C52Q39125988-451EF2D5-324F-4103-A26B-8FB2A15DF580Q40162046-08B33E30-EB20-496F-96FE-27CE82DDC7C6Q41929473-4F041192-811E-41B2-9B07-6C33164F3B67Q55105781-02ED35BD-1975-4DCF-AA8B-0AA9B752EFBB
P2860
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
description
1978 nî lūn-bûn
@nan
1978 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1978 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
name
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
@ast
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
@en
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
@nl
type
label
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
@ast
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
@en
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
@nl
prefLabel
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
@ast
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
@en
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
@nl
P2093
P3181
P356
P1476
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
@en
P2093
M A Friedman
M E Billingham
M J Bozdech
P304
P3181
P356
10.1001/JAMA.240.15.1603
P407
P577
1978-10-06T00:00:00Z